Gastric Carcinoma Marker Antibody (3H11): sc-52850

Gastric Carcinoma Marker Antibody (3H11) is a mouse monoclonal IgG1 antibody that detects the Gastric Carcinoma Marker protein of human origin by enzyme-linked immunosorbent assay (ELISA). Anti-Gastric Carcinoma Marker antibody (3H11) is available as the non-conjugated form, specifically designed to aid in the identification and treatment of gastric carcinoma, a malignancy that can arise in any part of the stomach and has the potential to metastasize to other organs, including the esophagus, small intestine, liver, pancreas, lungs, colon, and ovaries. Gastric Carcinoma Marker (3H11) antibody recognizes a protein that plays a crucial role in the progression of this disease, as Gastric Carcinoma Marker is involved in the regulation of cell adhesion and signaling pathways that influence tumor growth and metastasis. Understanding Gastric Carcinoma Marker protein function is vital, as this knowledge can provide insights into the mechanisms of gastric cancer development and progression, ultimately guiding therapeutic strategies. Gastric Carcinoma Marker (3H11) monoclonal antibody serves as an essential tool for researchers and clinicians aiming to explore the complexities of gastric carcinoma and develop targeted treatments.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Gastric Carcinoma Marker Antibody (3H11) References:

1. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.  |  Hammarström, S. 1999. Semin Cancer Biol. 9: 67-81. PMID: 10202129
2. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma.  |  Yashiro, M., et al. 2006. Eur J Cancer. 42: 2397-403. PMID: 16890424
3. [Clinical and prognostic significance of protein and gene expression of orotate phosphoribosyltransferase in gastric carcinoma].  |  Sakurai, Y., et al. 2006. Gan To Kagaku Ryoho. 33: 1111-8. PMID: 16912530
4. Increased expression of angiogenin in gastric carcinoma in correlation with tumor angiogenesis and proliferation.  |  Chen, Y., et al. 2006. World J Gastroenterol. 12: 5135-9. PMID: 16937522
5. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.  |  Rojo, F., et al. 2006. J Clin Oncol. 24: 4309-16. PMID: 16963731
6. Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma.  |  Lee, KH., et al. 2006. Oncol Rep. 16: 823-30. PMID: 16969501
7. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.  |  Sakamoto, J., et al. 2006. Cancer Sci. 97: 1248-54. PMID: 17034367
8. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma.  |  Hishinuma, M., et al. 2006. Histopathology. 49: 479-86. PMID: 17064293
9. Testicular metastasis from gastric carcinoma.  |  Qazi, HA., et al. 2006. Urology. 68: 890.e7-8. PMID: 17070383
10. Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation.  |  Shi, LH., et al. 2006. World J Gastroenterol. 12: 6285-9. PMID: 17072950
11. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.  |  Bacac, M., et al. 2016. Clin Cancer Res. 22: 3286-97. PMID: 26861458
12. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.  |  Klein, C., et al. 2017. Oncoimmunology. 6: e1277306. PMID: 28405498